Ka Zhang

Dr. Ka Zhang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
YJYifan Jia
Yifan Jia
XSXin Shu
Xin Shu
XYXiaoan Yang
Xiaoan Yang
HSHaixia Sun
Haixia Sun
HCHuijuan Cao
Huijuan Cao
YYYang Yang
Yang Yang
Background: Umbilical cord mesenchymal stem cells (UCMSCs) have been demonstrated to have good therapeutic effects in the treatment of HBV-related liver diseases. However, the therapeutic effect of UCMSCs on HBV-related liver failure and liver cirrhosis and the variations in the efficacy of UCMSCs after different treatment courses remain poorly understood. Therefore, this study was designed to answer these two questions. Methods: This was an observational study that retrospectively considered a 3-year period during which 513 patients who received stem cell infusion and met the criteria of hepatic failure and liver cirrhosis were identified from the databases of the Third Affiliated Hospital of Sun Yat-sen University. The eligible patients were categorized into the liver failure group and liver cirrhosis group. The two groups were divided into different subgroups according to the duration of stem cell therapy. In the liver failure group, group A received more than 4 weeks and group B received less than 4 weeks of stem cell therapy. In the liver cirrhosis group, patients who received more than 4 weeks of stem cell therapy belonged to group C, and the patients in group D received less than 4 weeks of stem cell therapy. The patients were followed up for 24 weeks. The demographics, clinical characteristics, biochemical factors, and model for end-stage liver disease (MELD) scores were recorded and compared among different groups. Results: A total of 64 patients met the criteria for liver failure, and 59 patients met the criteria for liver cirrhosis. After UCMSC treatment, the levels of alanine aminotransferase (ALT), glutamic-oxaloacetic transaminase (AST), and total bilirubin (TBIL) at all postbaseline time points were significantly lower than those at baseline in the liver failure group and liver cirrhosis group; the prothrombin activity (PTA) and MELD scores gradually improved in only the liver failure group. Four weeks after UCMSC treatment, patients who received prolonged treatment with UCMSCs had a larger decrease in TBIL levels than patients who terminated treatment with UCMSCs. After more than 4 weeks of UCMSC treatment, there were no statistically significant differences in the changes in ALT, AST, TBIL, and PTA values and MELD scores between patients with liver failure who received prolonged treatment with UCMSCs and patients with liver cirrhosis who received prolonged treatment with UCMSCs at any time point. However, the median decrease and cumulative decrease in the TBIL level of patients with liver failure with a standard 4-week treatment course were larger than those of patients with liver cirrhosis with a standard 4-week treatment course. Conclusion: Peripheral infusion of UCMSCs showed good therapeutic effects for HBV-related liver failure and liver cirrhosis. Prolonging the treatment course can increase the curative effect of UCMSCs for end-stage liver disease, especially for patients with cirrhosis.

18 March 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
KZKa Zhang
Ka Zhang
YLYanqiong Liu
Yanqiong Liu
XYXiaoan Yang
Xiaoan Yang
HSHaixia Sun
Haixia Sun
XSXin Shu
Xin Shu
GLGang Li
Gang Li

29 April 2020 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
FCFengjuan Chen
Fengjuan Chen
KZKa Zhang
Ka Zhang
YHYilin Huang
Yilin Huang
FLFang Luo
Fang Luo
KHKunpeng Hu
Kunpeng Hu
QCQingxian Cai
Qingxian Cai
Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis and high mortality. To identify key genes associated with HCC and the underlying mechanisms, we performed weighted correlation network analysis (WGCNA) of potential key genes of HCC. We identified 17 key genes closely related to HCC by yellow module combined with PPI analysis. Verification of the role of these genes revealed that SPC25 knockdown results in a significant decrease in proliferation and metastasis of HCC cells and increased protein levels of components of the p53 pathway in vitro . In summary, we identified that SPC25 is a potential tumor‐promoting factor in HCC and may act via the p53 pathway.

20 August 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
KZKa Zhang
Ka Zhang
HSHaixia Sun
Haixia Sun
HCHuijuan Cao
Huijuan Cao
YJYifan Jia
Yifan Jia
XSXin Shu
Xin Shu
XYXiaoan Yang
Xiaoan Yang
Background: The results of a previous study verified that umbilical cord mesenchymal stem cells (UCMSCs) have good therapeutic effects for the treatment of HBV-related acute-on-chronic liver failure (ACLF) and liver cirrhosis (LC). Nevertheless, it is still unknown whether the effects of UCMSCs are affected by recipient age. Methods: Patients treated with UCMSCs who met the criteria of HBV-related ACLF and liver cirrhosis were identified in this retrospective observational study. Patients were divided into subgroups according to the World Health Organization (WHO) age criteria (< 45 vs. ≥ 45 years). Group A included young ACLF patients (< 45 y), and group B included older ACLF patients (≥ 45 y). Young LC patients (< 45 y) were assigned to group C, and group D included older LC patients (≥ 45 y). Patients’ clinical characteristics, demographics, biochemical factors, and model for end-stage liver disease (MELD) scores were compared for 24 weeks. Results: Sixty-four ACLF patients and 59 LC patients were enrolled in this study. Compared with patients in groups B and C, patients in group A did not show significant superiority in terms of the levels of ALT, AST, TBIL, AFP, and PTA and MELD scores. However, the median decrease and cumulative decrease in the TBIL and ALT levels of patients in group C were larger than those of patients in group D after four weeks of UCMSC transfusions. For older patients (≥ 45 y), the cumulative decrease and the median decrease in the TBIL of ACLF patients were significantly greater than those of LC patients after UCMSC treatment. However, the median decrease in ALT levels of ACLF patients was significantly greater than that of LC patients during UCMSC treatment, and the cumulative decrease in ALT levels of ACLF patients was significantly greater than that of LC patients at all time points. Conclusion: The therapeutic effects of UCMSCs for HBV-related acute-on-chronic liver failure and liver cirrhosis varied partly by patient age. Assessing patient age is necessary prior to UCMSC clinical use.

1 August 2016 in Medicine
Verified
Journal Article
Open access
KZKa Zhang
Ka Zhang
HCHong Cao
Hong Cao
JLJiayi Liang
Jiayi Liang
XSXin Shu
Xin Shu
HSHaixia Sun
Haixia Sun
QXQihuan Xu
Qihuan Xu
The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D). All patients were followed for 48 weeks. Efficacy and safety analyses were performed. Patients in group a received 135 μg of PEG-INF-α2a by subcutaneous injection once weekly for 48 weeks. Patients in the ADV add-on group received 135 μg of PEG-INF-α2a subcutaneously once weekly and received 10 mg of ADV administered once daily for 48 weeks. HBV DNA, HBsAg, HBeAg, and hepatitis B e antibody levels were determined. Responses were determined at week 12 (ADV add-on), the end of treatment for PEG-INF-α2a (48weeks) and ADV (EOT) and at the end of 96 weeks of follow-up (EOF). The rate of HBV DNA loss were higher in the combination groups than group A at the week 12, week 48, the EOT and EOF (P < 0.05). The rates of HBeAg seroconversion and HBsAg loss were similar among the treatment groups (P>0.05). The alanineaminotransferase (ALT) normalization rate was higher in the combination group than group A only at the EOT (P = 0.007). By the EOF, the patients with ADV added at week 12 achieved higher rates of HBV DNA loss (71.9%), HBeAg seroconversion (50.0%), HBsAg loss (15.6%), and ALT normalization (78.1%). PEG-INF-α2a plus ADV combination therapy is safe and superior to PEG-INF-α2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss. Adding ADV at week 12 may be an optimal combination strategy.

1 December 2021 in Liver Research
Verified
Journal Article
Open access
XSXin Shu
Xin Shu
HSHaixia Sun
Haixia Sun
XYXiaoan Yang
Xiaoan Yang
YJYifan Jia
Yifan Jia
PXPeiyan Xu
Peiyan Xu
KZKa Zhang
Ka Zhang
Effective hepatic blood flow (EHBF) decreases with liver disease progression, and identifying liver pathology is critical for patients with liver disease. This study was designed to elucidate the correlation between EHBF and liver pathology and explore the potential of EHBF for predicting the degree of liver pathology. In this study, 207 patients with hepatitis B virus (HBV) who underwent liver biopsy and indocyanine green (ICG) clearance tests were enrolled. EHBF was measured using the ICG clearance test, and liver tissue was histologically analyzed to determine the pathological stage according to the Scheuer scoring system. Demographic data, biochemical indexes, and FibroScan data were collected for statistical analysis. EHBF levels decreased as the liver histological stages of inflammation and fibrosis increased (P < 0.01). EHBF was significantly negatively associated with the levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, aspartate aminotransferase-to-platelet ratio index, fibrosis index based on the four factors, and liver stiffness measurement (P < 0.05). The EHBF levels of patients without liver inflammation (G0) were significantly higher than those of patients with liver inflammation (G1–4) (P < 0.001). The area under the receiver operating characteristic curve (AUROC) value for discriminating patients without liver inflammation was 0.827, and the optimal cutoff value was 0.936 L/min. The EHBF levels of patients with severe liver inflammation (G4) were significantly lower than those of patients with G0–3 liver inflammation (P < 0.001). The AUROC value for discriminating patients with severe liver inflammation was 0.792, and the optimal cutoff value was 0.552 L/min. The EHBF levels of patients without liver fibrosis (S0) were significantly higher than those of patients with liver fibrosis (S1–4) (P < 0.001). The AUROC value for discriminating patients without liver fibrosis was 0.633, and the optimal cutoff value was 1.173 L/min. The EHBF levels of patients with liver cirrhosis (S4) were significantly lower than those of patients with S0–3 liver fibrosis (P < 0.001). The AUROC value for discriminating patients with liver cirrhosis (S4) was 0.630, and the optimal cutoff value was 0.562 L/min. EHBF levels and liver pathology are significantly correlated. EHBF could effectively reflect liver inflammation and fibrosis in patients infected with HBV, especially for patients without liver inflammation or liver fibrosis.